Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

562 Press Releases
DateTitleCompany
22 Jan 13 Pfizer Partnership Organizations Significantly Benefit From Pfizer’s Global Health Fellows Program Pfizer Inc.,
Published by
Business Wire
22 Jan 13 Inspra (eplerenone) accepted for use within NHS Wales Pfizer
16 Jan 13 Data Shows Peak Cold and Flu Season is Here for Philadelphia Pfizer,
Published by
Business Wire
16 Jan 13 Data Shows Peak Cold and Flu Season is Here for Chicago Pfizer,
Published by
Business Wire
14 Jan 13 Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States Pfizer Inc.,
Published by
Business Wire
08 Jan 13 Pfizer Receives European Approval To Expand Use Of Prevenar 13 To Older Children And Adolescents Aged 6 To 17 Years For The Prevention Of Pneumococcal Disease Pfizer Inc.,
Published by
Business Wire
02 Jan 13 U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation Pfizer Inc.,
Published by
Business Wire
26 Dec 12 ELIQUIS® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation Pfizer,
Published by
Business Wire
18 Dec 12 Pfizer Invites Public To View And Listen To Webcast Of January 29 Conference Call With Analysts Pfizer Inc.,
Published by
Business Wire
17 Dec 12 Pfizer Declares First-Quarter 2013 Dividend Pfizer Inc.,
Published by
Business Wire
14 Dec 12 U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis Pfizer Inc.,
Published by
Business Wire
09 Dec 12 ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended Treatment Pfizer Inc.,
Published by
Business Wire
07 Dec 12 Pfizer disappointed over NICE’s preliminary recommendation for new kidney cancer medicine - axitinib Pfizer Ltd
05 Dec 12 Tanzania Expands Immunization Program To Include Pfizer’s Prevenar 13 For Prevention Of Pneumococcal Disease Pfizer Inc.,
Published by
Business Wire
05 Dec 12 Pfizer Presents Phase 2 Data Showing Investigational Therapy PD-0332991 Plus Letrozole Significantly Improved Progression Free Survival Compared With Letrozole Alone In Patients With ER Positive, HER2 Negative Advanced Breast Cancer Pfizer Inc.,
Published by
Business Wire
01 Dec 12 Pfizer Completes Sale of Nutrition Business to Nestlé Pfizer Inc.,
Published by
Business Wire
29 Nov 12 Pfizer to Present Clinical Data from Its Hematology Portfolio at the 54th Annual Meeting of the American Society of Hematology Pfizer Oncology,
Published by
Business Wire
28 Nov 12 Pfizer Acquires NextWave Pharmaceuticals, Inc. Pfizer,
Published by
Business Wire
26 Nov 12 Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013 Pfizer Inc.,
Published by
Business Wire
21 Nov 12 ELIQUIS®(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation Pfizer Inc.,
Published by
Business Wire
19 Nov 12 Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release As Treatment For Patients With Fibromyalgia Pfizer Inc.,
Published by
Business Wire
16 Nov 12 Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As Adjunctive Treatment In Adult Patients With Partial Onset Seizures Pfizer Inc.,
Published by
Business Wire
07 Nov 12 U.S. Food and Drug Administration Approval of XELJANZ® (tofacitinib citrate) and Invitation to Media Briefing from Pfizer Pfizer Inc.,
Published by
Business Wire
07 Nov 12 U.S. Food and Drug Administration Approves Pfizer’s XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate Pfizer Inc.,
Published by
Business Wire
02 Nov 12 Portola, Bristol-Myers Squibb and Pfizer Sign Clinical Collaboration Agreement to Study ELIQUIS® and Portola’s Universal Factor Xa Inhibitor Antidote PRT4445 Pfizer Inc.,
Published by
Business Wire
01 Nov 12 Pfizer Reports Third-Quarter 2012 Results Pfizer Inc.,
Published by
Business Wire
29 Oct 12 Pfizer Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to November 1, 2012 Due To Expected Severe Weather Conditions Pfizer Inc.,
Published by
Business Wire
26 Oct 12 Pfizer Declares A 22-Cent Fourth-Quarter 2012 Dividend Pfizer Inc.,
Published by
Business Wire
24 Oct 12 Pfizer’s XALKORI® Receives Conditional Marketing Authorization from the European Commission for the Treatment of Adults with Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU Pfizer Inc.,
Published by
Business Wire
22 Oct 12 Pfizer To Acquire NextWave Pharmaceuticals, Inc. Pfizer Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.